Jacob GlanvilleFounder

United States - San Francisco Bay Area

Jake is a serial biotechnology startup founder, and computational immune engineer. Currently the Founder and CEO of Centivax, previously the Founder and CEO of Distributed Bio, which had a successful exit in 2020. Pfizer, Stanford, and UC Berkeley alum. Affiliate Professor of USAC. Advisory board of USF Biotechnology PSM. He is a recipient of the Gates Foundation Grand Challenge "Ending the Pandemic Threat" for his broad-spectrum vaccine technology, the history of that project recorded in Netflix docuseries "Pandemic: How to Prevent an Outbreak." At DBio and Centivax, he designed the core antibody engineering and Universal Vaccine technologies, built and grew the teams, and developed the strategy to create a profitable self-sufficient therapeutics company. In academia he has developed seminal methods in the fields of high-throughput antibody repertoire sequencing (PNAS 2009), repertoire decoding algorithms (Nature 2017), single-cell TCR receptor & phenotype sequencing (Nature Biotech, 2014), deconstructing genetic variation in the adaptive immune system (Nature Communications 2015, Nature Reports 2016, PNAS 2011, TI 2017), and computationally guided antibody library engineering (JMB 2011, JMB 2013, COSB 2015).
He is a Stanford University Scientific Advisory Committee member for the Sean Parker Center for Allergy and Asthma Research, a Scientific Advisory Board member for the University of San Francisco's Biotechnology program, a repeat Gates Foundation/Stanford University Computational and Systems Immunology Grant Recipient while a PhD Candidate with Mark Davis at Stanford, a Recipient of Pfizer Achievement award 2010 while Principal Scientist at Pfizer.

Full CV: http://hackbio.com/jacob_glanville_cv.pdf
Company: http://www.distributedbio.com